-

04:01:05 AM

ADMP Stock News

ADMP - Adamis Pharmaceuticals Corp

05/25/23 4:26 PM

Nasdaq : ADMP

acquisitionlow float

Adamis Pharmaceuticals Announces Closing of the Merger with DMK Pharmaceuticals

DMK CEO, Ebrahim (Eboo) Versi, MD, PhD, named CEO and Chairman of the combined company Combined company will have commercial products and a library of development candidates, including two clinical stage programs DPI-125, the lead development program, is a clinical stage therapeutic under

RHEA-AI

neutral

05/19/23 12:00 PM

Nasdaq : ADMP

low float

Adamis Pharmaceuticals Announces Reverse Stock Split

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, announced today that it will effect a 1-for-70 reverse stock split of its common stock that will become effective on May 22, 2023, at 12:01 a.m., Eastern

RHEA-AI

neutral

05/15/23 4:47 PM

Nasdaq : ADMP

earningslow float

Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company focused on developing and commercializing products in various therapeutic

RHEA-AI

neutral

05/08/23 4:05 PM

Nasdaq : ADMP

earningslow float

Adamis Pharmaceuticals Schedules First Quarter 2023 Financial Results Conference Call and Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory

RHEA-AI

neutral

03/16/23 4:24 PM

Nasdaq : ADMP

earningslow float

Adamis Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid

RHEA-AI

neutral

03/14/23 4:01 PM

Nasdaq : ADMP

earningslow float

Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory

RHEA-AI

neutral

03/14/23 8:30 AM

Nasdaq : ADMP

offeringlow float

Adamis Pharmaceuticals Announces $3.0 Million Registered Direct Offering

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory

RHEA-AI

neutral

02/27/23 4:05 PM

Nasdaq : ADMP

acquisitionlow float

Adamis Pharmaceuticals and DMK Pharmaceuticals Announce Agreement and Plan of Merger

Combined company will have commercial products and a library of development candidates, two of which are clinical stage Will be under the leadership of DMK CEO, Dr. Ebrahim (Eboo) Versi MD, PhD Lead development program will be a clinical stage therapeutic under development for the treatment of

RHEA-AI

very positive

02/22/23 4:01 PM

Nasdaq : ADMP

low float

Nasdaq Grants Adamis Pharmaceuticals’ Request for Extension to Comply with Continued Listing Requirements

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory

RHEA-AI

very positive

11/14/22 4:10 PM

Nasdaq : ADMP

earningslow float

Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

ADMP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.adamispharmaceuticals.com
CeoDennis Carlo
Security nameAdamis Pharmaceuticals Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees12
Tags
- Health Technology
- Pharmaceuticals: Other
- Pharmaceuticals: Major
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address11682 El Camino Real Ste 300
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18589972400

About Adamis Pharmaceuticals Corp

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements